[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100460013":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":25,"locations":34,"responsibleParty":136,"collaborators":10,"id":138,"slug":139,"hasResults":140,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":140,"sex":146,"minAge":147,"maxAge":148,"enrollmentInfo":149,"targetDuration":10,"studyType":152,"phases":10,"briefSummary":153,"conditions":154,"keywords":157,"overallStatus":37,"whyStopped":10,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":169},{"fullName":5,"class":6},"Princess Maxima Center for Pediatric Oncology","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Relapsed leukemia",null,"T-ALL:\n\nFirst relapse with high MRD after re-induction Newly diagnosed with high MRD after consolidation\n\nB-ALL:\n\n1st relapse high risk group, Second or higher relapse, post CAR-T or post HSCT\n\nAML:\n\nSecond or higher relapse",[13],"Other: Advice",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Advice","non-interventional study",[9],[20,23],{"name":21,"affiliation":5,"role":22},"Michel Zwaan, Prof. dr.","PRINCIPAL_INVESTIGATOR",{"name":24,"affiliation":5,"role":22},"Monique den Boer, Prof. dr.",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},"Uri Ilan, MD","CONTACT","+31889725206","iltb@prinsesmaximacentrum.nl",{"name":32,"role":28,"phone":33,"phoneExt":10,"email":30},"Anne Elsinghorst","+316 5000 6270",[35,51,65,79,94,108,122],{"facility":36,"status":37,"city":38,"state":10,"zip":10,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"UH Gent","RECRUITING","Ghent","Belgium","BE",{"type":42,"coordinates":43},"Point",[44,45],3.71667,51.05,{"lat":45,"lon":44},[48],{"name":49,"role":28,"phone":10,"phoneExt":10,"email":50},"Barbara de Moerloose","barbara.demoerloose@uzgent.be",{"facility":52,"status":37,"city":53,"state":10,"zip":10,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Righospitalet","Copenhagen","Denmark","DK",{"type":42,"coordinates":57},[58,59],12.56553,55.67594,{"lat":59,"lon":58},[62],{"name":63,"role":28,"phone":10,"phoneExt":10,"email":64},"Ruta Tuckuviene","ruta.tuckuviene@regionh.dk",{"facility":66,"status":37,"city":67,"state":10,"zip":10,"country":68,"countryCode":69,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Semmelweis","Budapest","Hungary","HU",{"type":42,"coordinates":71},[72,73],19.04045,47.49835,{"lat":73,"lon":72},[76],{"name":77,"role":28,"phone":10,"phoneExt":10,"email":78},"Balint Egyed","egyed.balint@semmelweis.hu",{"facility":80,"status":37,"city":81,"state":81,"zip":82,"country":83,"countryCode":84,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"Princess Máxima Center for Pediatric Oncology","Utrecht","3584CS","Netherlands","NL",{"type":42,"coordinates":86},[87,88],5.12222,52.09083,{"lat":88,"lon":87},[91],{"name":92,"role":28,"phone":10,"phoneExt":10,"email":93},"Anne A.L Elsinghorst","iLTB@prinsesmaximacentrum.nl",{"facility":95,"status":37,"city":96,"state":10,"zip":10,"country":97,"countryCode":98,"cosmosGeoPoint":99,"geoPoint":103,"contacts":104},"Vall d'Hebron","Barcelona","Spain","ES",{"type":42,"coordinates":100},[101,102],2.15899,41.38879,{"lat":102,"lon":101},[105],{"name":106,"role":28,"phone":10,"phoneExt":10,"email":107},"Pablo Velasco","velasco4@hotmail.com",{"facility":109,"status":37,"city":110,"state":10,"zip":10,"country":111,"countryCode":112,"cosmosGeoPoint":113,"geoPoint":117,"contacts":118},"Queen Silvia","Gothenburg","Sweden","SE",{"type":42,"coordinates":114},[115,116],11.96679,57.70716,{"lat":116,"lon":115},[119],{"name":120,"role":28,"phone":10,"phoneExt":10,"email":121},"Jonas Abrahamsson","vobjab@gmail.com",{"facility":123,"status":37,"city":124,"state":10,"zip":10,"country":125,"countryCode":126,"cosmosGeoPoint":127,"geoPoint":131,"contacts":132},"Newcastle Hospital","Newcastle","United Kingdom","UK",{"type":42,"coordinates":128},[129,130],-5.88979,54.21804,{"lat":130,"lon":129},[133],{"name":134,"role":28,"phone":10,"phoneExt":10,"email":135},"Frederik van Delft","frederik.van-delft@newcastle.ac.uk",{"type":137,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100460013","international-leukemia-target-board-100460013",false,"NCT05270096","International Leukemia Target Board","International Concerted Action to Allocate Children, Adolescents and Young Adults With Relapsed and Refractory Leukemia\u002FLymphoma to the Right Therapy.","iLTB","Inclusion criteria\n\n1. The patient has been diagnosed with a R\u002FR hematological malignancy;\n2. The patient is less than 18 years of age at the time of first diagnosis and less than 25 years at the time of inclusion with relapse\u002Frefractory hematological malignancy;\n3. The patient is treated in a pediatric\u002FAYA setting or study protocol, with no current standard of care treatment;\n4. The patients' life expectancy is at least 6 weeks;\n5. The patient has undergone any sort of molecular profiling of his\u002Fher tumor and the re-sults of this analysis are available;\n6. The patient has undergone flow cytometry in a certified lab and results are available;\n7. Written informed consent of patient and\u002For parent(s)\u002Fguardian(s) to discuss the patient in the iLTB according to local law and legislation has been obtained.\n\nExclusion criteria: none defined","ALL","0 Years","25 Years",{"count":150,"type":151},600,"ESTIMATED","OBSERVATIONAL","The iLTB is a proof-of-concept initiative for children with r\u002Fr hematological malignancies, in which available treatment options will be prioritized by actionable events in a harmonized and uniform setting across Europe by a team of biologists, bio-statisticians, bio-informaticians, disease experts, geneticists, flow-experts, clinical trial physicians and also the treating physician.\n\nThe iLTB will discuss molecular (genetic lesions), immunophenotypic\u002Fsurface antigen markers information and, if available, drug response profiles to prioritize these events taking into account the treatment history and treatment intention (bridging to hematopoietic stem cell transplanation\u002FCAR-T or palliative) of each patient followed by a registry to monitor how often iLTB advice has been followed, which other therapy was chosen (off-label, compassionate use) and what the patient outcome is at an aggregated level.\n\nAs such the iLTB is non-interventional as it mainly provides advice and registers data on patients discussed in the iLTB.",[155,156],"Relapsed Hematologic Malignancy","Refractory Hematologic Malignancy",[158,9,159],"Tumor board","Treatment prioritization","2026-01-07",{"date":162,"type":163},"2026-01-09","ACTUAL",{"date":165,"type":163},"2022-12-31",{"date":167,"type":151},"2032-06-01",{"name":5,"class":6},7]